Accrued Expense	3 Months Ended
Mar. 31, 2024
Accrued Expense:
Accrued Expense	6. Accrued Expense As of March 31, 2024, current liabilities included accrued expenses of $2.0 million, comprised primarily of accrued clinical trial expenses of $1.4 million, employee vacation and bonus expenses of $0.2 million, legal and patent fees of $0.2 million, professional fees of $0.1 million and other accrued expenses of $0.1 million. As of December 31, 2023, current liabilities included accrued expenses of $1.3 million, comprised primarily of expenses related to the Company’s clinical trial for prexigebersen in AML of $0.8 million, accrued employee vacation and bonus expenses of $0.2 million, professional and consulting fees of $0.1 million, legal and patent fees of $0.1 million and other accrued expenses of $0.1 million.

Accrued Expense

3 Months Ended

Mar. 31, 2024

6. Accrued Expense

As of March 31, 2024, current liabilities included accrued expenses of $2.0 million, comprised primarily of accrued clinical trial expenses of $1.4 million, employee vacation and bonus expenses of $0.2 million, legal and patent fees of $0.2 million, professional fees of $0.1 million and other accrued expenses of $0.1 million. As of December 31, 2023, current liabilities included accrued expenses of $1.3 million, comprised primarily of expenses related to the Company’s clinical trial for prexigebersen in AML of $0.8 million, accrued employee vacation and bonus expenses of $0.2 million, professional and consulting fees of $0.1 million, legal and patent fees of $0.1 million and other accrued expenses of $0.1 million.